Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=28632728
&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests
in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215
Downregulation of serum metabolite GTA-446 as a novel potential marker for early
detection of colorectal cancer
#MMPMID28632728
Hata T
; Takemasa I
; Takahashi H
; Haraguchi N
; Nishimura J
; Hata T
; Mizushima T
; Doki Y
; Mori M
Br J Cancer
2017[Jul]; 117
(2
): 227-232
PMID28632728
show ga
BACKGROUND: We previously reported that GTA-446 may be a useful biomarker for
early detection of colorectal cancer. In the present study, we confirmed the
clinical feasibility of GTA-446 as a screening tool for colorectal cancer with a
novel measurement system developed for clinical use. We also improved sensitivity
by analysing GTA-446 levels according to gender. METHODS: Serum samples were
collected from 225 colorectal cancer patients and 916 healthy volunteers to
measure GTA-446 levels by flow injection analysis-mass spectrometry. RESULTS:
GTA-446 levels were downregulated in colorectal cancer patients compared with the
healthy volunteers, and in females compared with the males in both groups.
Receiver operating characteristic curve analysis revealed an optimal cut-off of
2.72??mol?l(-1) in males and 1.87??mol?l(-1) in females, with a large area under
the curve of 0.89-0.93. The sensitivity and specificity were 90.4% and 84.9% for
males, 85.2% and 80.5% for females, and 83.3% and 84.8% for all subjects,
respectively. CONCLUSIONS: GTA-446 is a clinically relevant biomarker for
colorectal cancer with high sensitivity when analysed by gender. Thus, GTA-446 is
a promising tool for primary colorectal cancer screening to identify populations
at a higher risk of colorectal cancer, with an emphasis on early detection.
free
free
free
